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Simple Summary: Despite its varying sensitivity and decreased specificity, chromogranin A
(CgA) is the most widely used biomarker for neuroendocrine tumors. The most common factor
affecting its diagnostic accuracy is the use of proton pump inhibitors (PPIs). Our aim was to
investigate circulating miRNA expression profiles in pancreatic neuroendocrine tumors (pNET) and
pheochromocytomas/paragangliomas (PPGL) to find miRNAs which could be used as biomarkers
along with CgA in these patients. MiRNA expression profiles were determined with next generation
sequencing and validated by quantitative real time PCR in 74 samples obtained from patients and
healthy volunteers treated with PPI. We observed a global downregulation of miRNAs in NET
compared to controls. A set of miRNAs in combination with CgA resulted in the best discrimination
of pNET irrespective of PPI treatment and a combination of miRNAs increased the diagnostic utility
of CgA even in pNET patients with low CgA.
Abstract: Chromogranin A (CgA) is the most widely accepted biomarker for neuroendocrine tumors
(NET) but its diagnostic accuracy is dependent on tumor type and the use of proton-pump inhibitors
(PPI). We investigated the diagnostic value of circulating miRNAs along with CgA in pancreatic
neuroendocrine tumors (pNET). 74 serum samples from patients with pNET (n = 25, nonfunctioning),
pheochromocytoma/paraganglioma (PPGL, n = 20), healthy individuals with normal CgA (n = 29)
including 10 samples from 5 healthy individuals with and without current PPI treatment were
collected. MiRNA expression profiles were determined using next-generation sequencing, followed
by validation with individual TaqMan assays. A global downregulation of miRNAs was observed in
patients with NET compared to controls. MiRNA expression of 33 miRNAs was able to discriminate
tumor samples from controls. No miRNA alone could be considered as an applicable biomarker
for pNET or PPGL. However, using a logistic model, the combination of a set of miRNAs increased
the discriminatory role of CgA irrespective of PPI treatment. In pNET patients with normal CgA
level our regression model yielded high (89.4%) diagnostic accuracy (AUC: 0.904, sensitivity: 66.6%,
specificity: 96.5%). A set of miRNAs increased the diagnostic utility of CgA in pNET even in patients
with low CgA.
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1. Introduction
Chromogranins are polypeptide prohormones being the major constituents of dense-core secretory
granules in neuroendocrine cells and they are co-secreted with peptide hormones and amines [1].
Neuroendocrine tumors (NETs) originate from neuroendocrine cells distributed widely throughout
the body [2]. They are rare neoplasms but their incidence and prevalence are steadily rising [3].
Pancreatic NET (pNET) is the most common neuroendocrine tumor that can either be functioning or
nonfunctioning according to hormone production [2]. Nonfunctioning (NF) pNETs comprising the
largest group of pNETs being asymptomatic result in delayed diagnosis and often present as metastatic
at diagnosis that significantly affect prognosis and survival [2,4].
An elevated level of circulating CgA has been associated with almost all tumor types of the
neuroendocrine system [1,5], but its sensitivity varies between 47–100% depending on tumor type
(100%, in gastrinomas, ~89% in pheochromocytomas, and ~69% in nonfunctioning pNETs) [1,6–8].
In addition, many oncological and non-oncological conditions, including renal failure, non-endocrine
tumors (e.g., prostate, breast, thymus, uterus, colon), chronic gastritis, and current proton pump
inhibitor therapy (PPIs) decrease the specificity CgA [6,9], but CgA is the only routinely measured
circulating marker in pNET. Previous studies, including one from our research group, showed that both
short- and long-term applications of PPIs and other acid-suppressive medications result in a significant
increase of CgA in blood, thus decreasing its clinical utility in the management of NETs [10,11].
Neuron-specific enolase (NSE) is a cytosolic enzyme of neurons and neuroendocrine cells,
that is predominantly expressed in small-cell lung cancer and poorly differentiated NETs [12,13].
Its diagnostic value, particularly its specificity for neuroendocrine tumors is rather poor [8,14,15].
5-Hydroxyindoleacitic acid (5-HIAA), as the main metabolite of serotonin, is a useful biomarker of
NETs in patients with carcinoid syndrome [12]. Other biomarkers, such as insulin, glucagon, or gastrin
are specific for subtypes of neuroendocrine cells [12].
Pheochromocytomas/paragangliomas (PPGLs) are rare neuroendocrine tumors of chromaffin cell
origin. These are found in the adrenal medulla (pheochromocytomas, PCC) and the paravertebral
ganglia of the nervous system (paragangliomas, PGL) [16]. They can produce catecholamines, but PGLs
located above the diaphragm are often non-secretory [16]. In PPGL, as CgA is co-secreted with
catecholamines, besides the determination of catecholamines and their metabolites, elevated CgA may
indicate tumor mass and malignancy; therefore, it may be used to monitor clinical response and tumor
relapse especially when the measurement of plasma metanephrines is not accessible [16].
Similarly to gene expression, miRNA expression is also cell type-specific and due to their presence
in circulation and their stability, they are considered as promising biomarker candidates in several
tumor types [17,18]. Their previously described expression alterations in pNET and PPGL raise their
potential usefulness as circulating biomarkers [19,20]. A multianalyte biomarker (NETest) encompassing
51 different NET-related transcripts showed a significantly more sensitive and efficient method in
NET diagnosis compared to single biomarkers [21], however, its availability and costs may limit its
usefulness [12].
We aimed to investigate the serum miRNA expression profile in patients with pNET to identify
potentially useful miRNA biomarkers. PPGL and healthy individuals with and without PPI treatment
were also studied to challenge the diagnostic utility of identified miRNAs along with CgA.
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2. Results
2.1. Evaluation of Cell Contamination Based on miRNA Signature
As intracellular miRNA concentration is much higher compared to those measured in a cell-free
environment, cellular contamination is an important factor to avoid. Therefore, first, we assessed
whether cellular contamination in our serum samples was present. In the collected samples visually,
no sign of hemolysis could be seen. The ratio of red blood cell-enriched miR-451a to the reference
miR-23a-3p was revealed as the most sensitive method for the detection of hemolysis compared
to hemoglobin measurement techniques (Coulter® AcT diff Analyzer and spectrophotometric
method) [22]. Assessing miR-451a to miR-23a-3p ratio no red blood cell (RBC) contamination
was detected in any of our samples.MiRNAs which are considered indicating red-blood-cell or
platelet cellular contamination [23–25] also showed low variance (0.4 for miR-142-3p and 0.3 for
miR451a/miR-23a-3p, respectively). Only samples without cellular contamination were included.
2.2. Analysis of Circulating miRNAs by Next-Generation Sequencing
Our exploratory study included 24 samples: 8 pNET (4 patients with low- and 4 with high-CgA),
8 PPGL patients and 8 control samples from 6 healthy individuals (2 of them were also treated with PPI,
samples before and after PPI treatment were both included). Altogether, 1525 miRNA were detected
in NGS profiling of whole serum samples. While nine miRNAs were the most abundant with an
>500 UMI reads/sample representing 0.05% of all detected miRNAs, the great majority of miRNAs
(1461 of 1525, 95%) were in the low-expression range (below 50 UMI reads/sample) (Figure 1A,B). Total
(global) miRNA expression in patients with pNET or PPGL was significantly decreased compared to
normal controls (Figure 1C).
Low abundance (<50 UMI read number) miRNAs were excluded from further analysis because
these miRNAs could not be validated in our experimental set up [26]. 33 miRNAs differentiated
pNET/PPGL patients from normal controls irrespective of PPI treatment (Table 1, Figure 1D). In pNET
19 and 7 under- and over-expressed miRNA, while in PPGL 25 and 6 under- and over-expressed
miRNAs compared to healthy controls were found (Table 1). However, PNET and PPGL patients could
not be differentiated by serum miRNA expression (Figure 1D). Additionally, we did not find significant
differences in healthy controls before and after PPI treatment.
Expression of 19 miRNAs showed a significant correlation with serum CgA levels among which
hsa-let-7g-5p showed the strongest association (R = −0.73; p = 0.03077).
Table 1. 33 miRNAs differentially expressed among controls with or without PPI treatment vs. PPGL
vs. pNET groups. (“control&PPI” group includes all healthy controls with and without PPI treatment:
“tumor-free” healthy individuals irrespective of the usage of PPI).
miRNA ANOVA
p-Value
pNET vs. Control&PPI PGGL vs. Control&PPI pNET vs. PPGL
log2FC Post-hocp-Value log2FC
Post-hoc
p-Value log2FC
Post-hoc
p-Value
hsa-miR-223-3p 0.0015 −1.62 0.0304 −2.27 0.0235 0.65 1
hsa-miR-486-3p 0.0002 −1.56 0.0177 −2.51 0.0066 0.95 1
hsa-miR-451a 0.0003 −1.42 0.0257 −2.35 0.0058 0.93 1
hsa-miR-16-5p 0.0009 −1.48 0.0320 −2.00 0.0139 0.52 1
hsa-miR-25-3p 0.0001 −1.48 0.0153 −2.10 0.0054 0.62 1
hsa-miR-143-3p 0.0001 −1.35 0.0240 −2.34 0.0031 1.00 1
hsa-miR-101-3p 0.0040 −1.31 0.0823 −1.90 0.0273 0.60 1
hsa-miR-486-5p 0.0005 −1.27 0.0413 −2.50 0.0066 1.23 1
hsa-miR-425-5p 0.0000 −1.23 0.0178 −2.23 0.0024 0.99 1
hsa-miR-148a-3p 0.0010 −1.25 0.0322 −1.82 0.0146 0.57 1
hsa-miR-93-5p 0.0003 −1.29 0.0240 −1.97 0.0066 0.68 1
hsa-let-7g-5p 0.0000 −1.14 0.0178 −2.20 0.0024 1.06 1
hsa-let-7i-5p 0.0003 −1.06 0.0316 −1.89 0.0055 0.83 1
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Table 1. Cont.
miRNA ANOVA
p-Value
pNET vs. Control&PPI PGGL vs. Control&PPI pNET vs. PPGL
log2FC Post-hocp-Value log2FC
Post-hoc
p-Value log2FC
Post-hoc
p-Value
hsa-miR-92a-3p 0.0004 −1.05 0.0440 −2.05 0.0060 1.01 1
hsa-let-7a-5p 0.0003 −1.00 0.0235 −1.66 0.0064 0.66 1
hsa-miR-185-5p 0.0008 −1.02 0.0859 −2.23 0.0079 1.22 1
hsa-miR-342-3p 0.0029 −0.97 0.0624 −1.63 0.0249 0.66 1
hsa-miR-30e-5p 0.0001 −0.93 0.0295 −1.77 0.0031 0.84 1
hsa-miR-142-3p 0.0055 −0.85 0.1610 −1.71 0.0287 0.86 1
hsa-miR-30d-5p 0.0015 −0.88 0.0432 −1.57 0.0165 0.69 1
hsa-let-7b-5p 0.0029 −0.84 0.0539 −1.51 0.0261 0.67 1
hsa-let-7f-5p 0.0007 −0.75 0.0475 −1.41 0.0081 0.66 1
hsa-miR-199a-3p 0.0069 −0.77 0.1009 −1.47 0.0375 0.70 1
hsa-miR-103a-3p 0.0003 −0.74 0.0371 −1.38 0.0055 0.63 1
hsa-miR-26b-5p 0.0003 −0.65 0.0424 −1.31 0.0054 0.66 1
hsa-miR-6743-3p 0.0002 0.61 0.0179 0.45 0.0054 0.15 1
hsa-miR-4440 0.0000 0.65 0.0107 0.54 0.0031 0.11 1
hsa-miR-6717-5p 0.0000 0.66 0.0009 0.43 0.0007 0.23 1
hsa-miR-148a-5p 0.0000 0.89 0.0067 0.59 0.0054 0.30 1
hsa-miR-7155-5p 0.0002 0.96 0.0071 0.31 0.0358 0.65 1
hsa-miR-203a-3p 0.0006 1.54 0.0716 2.07 0.0066 −0.54 1
hsa-miR-6857-3p 0.0071 2.67 0.0316 0.49 0.6878 2.18 1
hsa-miR-4274 0.0055 3.09 0.0279 1.23 0.6318 1.86 1
PPGL: pheochromocytoma-paraganglioma; PPI: proton pump inhibitor treatment; pNET: pancreatic neuroendocrine
tumor, log2FC: log2fold change (counts); post-hoc p-value: p-value following Tukey post-hoc test adjusted by
Benjamini–Hochberg method for multiple testing correction.
2.3. miRNA Validation
Of the 33 significantly differently expressed miRNAs between controls and tumor sera samples
we selected 6 underexpressed miRNAs (let-7b-5p, let-7i-5p; miR-143-3p; miR-30d-5p; miR-451a;
miR-486-5p) in pNET/PPGL samples compared to controls) based on miRNA abundance for further
investigation. Additionally, we also validated the most overexpressed miR-203a-3p despite its relatively
lower abundance (avg. UMI read number in pNET/PPGL samples: 68 vs. avg. UMI read number in
controls: 19). The selected miRNAs were measured on an extended sample cohort consisting of 25 pNET
and 20 PPGL patients (together with those included in the exploratory cohort), and 29 control samples
(5 with PPI treatment, 24 without PPI treatment; including samples from our exploratory cohort).
All the 6 underexpressed miRNAs were confirmed by RT-qPCR as well (Figure 2A). After dissecting
tumor groups, the underexpression of miR-30d-5p, miR-451a, and miR-486-5p was significant in pNET
patients with high CgA levels and let-7b-5p in PPGL cases compared to healthy controls without PPI
treatment (Figure 2B).
The overexpression of miR-203a-3p was not confirmed by RT-qPCR in any of the samples but one
pNET patient with extremely high CgA (2490.8 ng/mL).
2.4. Association of miRNA Expression with Clinicopathological Parameters
We could not find a difference in miRNA expression profiles of pNET/PPGL samples compared to
healthy controls treated with PPI. However, let-7b-5p, let-7i-5p; miR-143-3p; miR-30d-5p; miR-451a
and miR-486-5p showed lower expression in samples with high (>100 ng/mL) CgA levels compared
to samples with normal CgA level (≤100 ng/mL) (Figure 3A). The expression of all 6 miRNAs
showed a negative correlation with serum CgA level when all samples were included in the analysis.
While investigating correlation in different patient groups the negative correlation between miRNAs and
CgA remained significant only in the healthy control group but not in pNET or PPGL group (Table 2).
Cancers 2020, 12, 2488 5 of 20
Cancers 2020, 12, x 5 of 21 
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Figure 1. MiRNA expression in the exploratory study. (A) MiRNA abundance in serum. (B) Expression
of the 9 most abundant miRNAs. (C) Global miRNA expression level among normal controls and
pNET/PCC samples. Error bars indicate mean ± SE. * represents p-value < 0.05. (D) 33 differentially
expressed miRNAs among different groups can discriminate against control and pNET/PCC samples.
Green indicates lower, red indicates higher expression.
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Table 2. CgA correlation with miRNA expression in the validation set (CgA vs. –dct).
All Samples
Correlation Sample Number Spearman p-value
CgA & hsa-let-7b-5p 74 −0.29 0.0125
CgA & hsa-let-7i-5p 74 −0.46 0.0000
CgA & hsa-miR-143-3p 74 −0.34 0.0029
CgA & hsa-miR-30d-5p 74 −0.39 0.0007
CgA & hsa-miR-451a 74 −0.50 0.0000
CgA & hsa-miR-486-5p 74 −0.39 0.0006
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Table 2. Cont.
Healthy Controls (with & without PPI)
Correlation Sample number Spearman p-value
CgA & hsa-let-7b-5p 29 −0.27 0.1599
CgA & hsa-let-7i-5p 29 −0.42 0.0249
CgA & hsa-miR-143-3p 29 −0.40 0.0293
CgA & hsa-miR-30d-5p 29 −0.39 0.0377
CgA & hsa-miR-451a 29 −0.40 0.0334
CgA & hsa-miR-486-5p 29 −0.17 0.3852
PPGL
Correlation Sample number Spearman p-value
CgA & hsa-let-7b-5p 20 −0.05 0.8256
CgA & hsa-let-7i-5p 20 −0.42 0.0655
CgA & hsa-miR-143-3p 20 −0.37 0.1069
CgA & hsa-miR-30d-5p 20 −0.35 0.1317
CgA & hsa-miR-451a 20 -0.38 0.1009
CgA & hsa-miR-486-5p 20 -0.45 0.0451
pNET
Correlation Sample number Spearman p-value
CgA & hsa-let-7b-5p 25 −0.04 0.8380
CgA & hsa-let-7i-5p 25 −0.22 0.2838
CgA & hsa-miR-143-3p 25 −0.14 0.5116
CgA & hsa-miR-30d-5p 25 −0.02 0.9157
CgA & hsa-miR-451a 25 −0.32 0.1198
CgA & hsa-miR-486-5p 25 −0.18 0.3892
Investigating miRNAs in relation to the tumor grade, in pNET patients a tendency of inverse
correlation between miRNAs: let-7i-5p, miR-30d-5p, and miR-451a and grade was observed (Figure 3B).
In samples obtained from PPGL patients only miR-486-5p showed an inverse correlation with
CgA (Table 2). As different miRNA signatures have been described in malignant vs. benign [27] and
sporadic vs. hereditary PPGL [28] we aimed to investigate serum miRNAs in correlation to these
clinicopathological parameters. We found that in serum samples obtained from PPGL patients with
germline mutations (SDHB, RET, VHL, or NF1) miR-486-5p and miR-30d-5p were downregulated
compared to sporadic patients (Figure 3C). In patients with SDHB germline mutation beside the
underexpression of miR-30d-5p and miR-486-5p, let-7b-5p and let-7i-5p also showed downregulation
compared to serum samples of patients with SDHB wild type (Figure 3D).
2.5. Diagnostic Value of the Circulating miRNAs in PPGL/pNET
In the discrimination of healthy controls from pNET and PPGL patients, we performed
receiver-operating characteristic (ROC) analysis for CgA and individual miRNAs. Binary logistic
regression models were generated for combinations of miRNAs and combinations of CgA with miRNAs.
Altogether 6 miRNAs (let-7b-5p, let-7i-5p, miR-143-3p, miR-30d-5p, miR-451a, and miR-486-5p) were
assessed individually and in combinations (Table 3). In the pNET group compared to CgA the use
of individual let-7b-5p, miR-30d-5p, miR-451a, and miR-486-5p in ROC analysis resulted in better
discrimination (Table 3). Additionally, the regression model of the combination of CgA with a panel of
4 (let-7b-5p, let-7i-5p, hsa-miR-143-3p, miR-30d-5p) miRNAs resulted in the best discrimination with
72.2% accuracy (AUC: 0.751; 75.8% sensitivity; 68% specificity) (Table 3).
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p-value < 0.05.
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Table 3. Diagnostic performance of CgA, individual miRNAs, and the best combination of CgA with miRNAs between different groups. *: Cut off values of CgA in
ng/mL and of miRNAs in dCt; **: Cut-off in binary logistic regression model. AUC: area under curve.
PPGL vs. Controls with & without PPI treatment AUC Cutoff * Sensitivity % Specificity % p-value
CgA 0.890 >102.3 95.0 72.4 <0.0001
Individual miRNAs
hsa-let-7b-5p 0.707 >12.5 90.0 48.3 0.0147
hsa-let-7i-5p 0.710 >5.7 100.0 3.4 0.0135
hsa-miR-143-3p 0.598 >7.7 100.0 27.6 0.2463
hsa-miR-30d-5p 0.643 >9.9 65.0 65.5 0.0914
miR-451a 0.678 >5.8 45.0 86.2 0.0353
miR-486-5p 0.660 >7.3 30.0 96.6 0.0586
Binary logistic regression model AUC cut-off ** Sensitivity % Specificity % p-value
Best of all combinations CgA+hsa-let-7b-5p+hsa-miR-143-3p+hsa-miR-486-5p 0.862 0.4 85.0 82.8 0.0085
pNET vs. Controls with & without PPI treatment AUC cut-off * Sensitivity % Specificity % p-value
CgA 0.672 >102.5 64.0 72.4 0.0308
Individual miRNAs
hsa-let-7b-5p 0.702 >12.9 80.0 62.1 0.0111
hsa-let-7i-5p 0.661 >7.9 80.0 51.7 0.0433
hsa-miR-143-3p 0.661 >9.0 100.0 41.4 0.0433
hsa-miR-30d-5p 0.675 >9.7 76.0 62.1 0.0276
miR-451a 0.692 >2.9 96.0 41.4 0.0159
miR-486-5p 0.712 >4.2 88.0 58.6 0.0078
Binary logistic regression model AUC cut-off** Sensitivity % Specificity % p-value
Best of all combinations CgA+hsa-let-7b-5p+hsa-let-7i-5p+hsa-miR-143-3p+hsa-miR-30d-5p 0.752 0.5 75.9 68.0 0.0351
CgA low pNET vs. Controls with & without PPI treatment AUCa cut-off * Sensitivity % Specificity % p-value
CgA 0.613 <79.6 100.0 37.9 0.3112
Individual miRNAs
hsa-let-7b-5p 0.651 >12.9 77.8 62.1 0.1751
hsa-let-7i-5p 0.517 <8.8 100.0 20.7 0.8772
hsa-miR-143-3p 0.646 >9.9 100.0 48.3 0.1920
hsa-miR-30d-5p 0.577 >9.4 77.8 55.2 0.4923
miR-451a 0.527 >2.9 88.9 41.4 0.8101
miR-486-5p 0.561 >4.2 66.7 58.6 0.5828
Binary logistic regression model AUC cut-off ** Sensitivity % Specificity % p-value
Best of all combinations CgA+hsa-let-7b-5p+hsa-let-7i-5p+hsa-miR-143-3p+hsa-miR-30d-5p+hsa-miR-486-5p 0.904 0.55 66.7 96.6 0.0342
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Clinically, the most challenging pNET patients are those with normal serum CgA levels
(<100 ng/mL). Therefore, miRNA expression profiles are of particular interest in these patients.
The use of the individual expression of let-7b-5p or miR-143-3p yielded better discrimination from
healthy controls compared to CgA alone (Table 3). However, the combination of CgA value with
an expression of 4 miRNAs in a logistic regression model showed the best discrimination between
pNET-low CgA group compared to healthy controls including normal or elevated CgA with the
accuracy of 89.4% (AUC: 0.904, sensitivity: 66.6%, specificity: 96.5%) (Table 3).
In our sample set all PPGL patients had elevated CgA level, and in line with this CgA, had
the highest discriminatory value with 81.6% accuracy (AUC: 0.889; 75% sensitivity, 86% specificity;
p = 0.0007). Using binary logistic regression model the combination of CgA with 3 miRNAs (let-7b-5p,
miR-143-3p and miR-486-5p) yielded higher specificity compared to CgA alone with 83.6% accuracy in
discrimination of normal samples from PPGL samples, however, with lower sensitivity (AUC: 0.862;
85% sensitivity; 82.7% specificity) (Table 3).
2.6. Analysis of Deregulated pNET/PPGL Tissue miRNAs in Serum Samples
To investigate the potential origin of miRNAs in serum, we collected the data of 12 studies reporting
tissue miRNA expression profiles in pNET [29–35] and PPGL [27,28,36–38]. By cross-referencing
differentially expressed miRNAs from those studies with our current findings 9 miRNAs in pNET
and 3 miRNAs in PPGL were found commonly dysregulated in both tissue and serum. (Table 4).
Among these, only miR-203a-3p was overexpressed both in pNET tissue and serum. All other
miRNAs were upregulated in tumor tissues and downregulated in serum samples. In PPGL,
while miR-101-3p showed higher expression in malignant vs. benign PPGLs, in serum, it was
downregulated compared to controls. However, miR-16-5p and miR-451a as putative tumor suppressor
miRNAs were downregulated in both tissue and serum (Table 4).
Table 4. Comparison of differentially expressed miRNAs in pNET/PCC tumor tissues vs. serum.
miRNAs common in both tissues and sera samples are indicated in the table.
pNET
miRNA
Corrected
p-Value
Controls pNET
Reference
avg. UMI Read Number
miR-103a-3p 0.0371 109 65
Roldo et al., 2006 [33] overexpressed in pNET+PACC vs. NP
Zimmermann et al., 2018 [35] negative correlation with Ki-67 in GEP-NET
miR-26b-5p 0.0423 115 73 Roldo et al., 2006 [33] overexpressed in pNET+PACC vs. NP
miR-143-3p 0.0240 110 43 Jiang et al., 2015 [29] overexpressed in INS vs pancreatic islet
miR-451a 0.0257 198 74 Jiang et al., 2015 [29] overexpressed in INS vs pancreatic islet
miR-25 0.0153 383 138 Zimmermann et al., 2018 [35] overexpressed in nodal met. vs. primary GEP-NET
miR-425-5p 0.01781 111 47 Zimmermann et al., 2018 [35] overexpressed in nodal met. vs. primary GEP-NET
miR-93-5p 0.0240 286 117 Grolmusz et al., 2018 [34] higher expression in higher grade pNET
miR-16-5p 0.0320 9670 3475 Zimmermann et al., 2018 [35] negative correlation with Ki-67 in GEP-NET
miR-203a-3p 0.0715 19 56 Roldo et al., 2006 [33] overexpressed in INS vs NF-pNET
PCC
miRNA
Corrected
p-Value
Controls PCC
Reference
avg. UMI Read Number
miR-101-3p 0.0273 209 56
Zong et al.2015 [36] higher expression in malignant vs. benign PCChigher expression in SDHD mutation-associated tumors
Patterson et al., 2012 [27] differentially expressed between malignant vs. benign PCC
miR-16-5p 0.0139 9670 2423 Meyer-Rochow et al., 2010 [37] underexpressed in malignant vs. benign PCC
miR-451a 0.005 198 39 Meyer-Rochow et al., 2010 [37] underexpressed in malignant vs. benign PCC
3. Discussion
Tumors of the neuroendocrine system are rare entities but represent serious diagnostic and
therapeutical challenges. Especially, when they are hormonally inactive, the diagnosis is usually
delayed due to a lack of specific circulating biomarkers. The delayed diagnosis influences prognosis
and survival [2]. Therefore, novel circulating biomarkers are needed. To our best knowledge, no study
on the diagnostic accuracy of circulating miRNAs in neuroendocrine tumors in relation to serum CgA
has been published.
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Our data revealed a low global miRNA expression (abundance) in sera of patients with
pNET/PPGL compared to normal controls. The same phenomenon was also observed in blood
samples obtained from patients with pituitary adenoma [26]. Interestingly, in tumor tissues, a general
downregulation of miRNAs compared to normal tissues was also detected suggesting their general
tumor-suppressive role instead of being oncogenes [39]. Based on the individual miRNA measurements,
Mitchell et al., 2008 [17] reported that the presence of tumors does not lead to a generalized increase
in circulating miRNAs. However, specific individual tumor-derived miRNAs can show increased
expression in circulation. With the technical advancement of NGS, total miRNA abundance can
be determined easier and more accurately than earlier used platforms (i.e., microarray) allowed.
Still, both the causes and the role of the decreased global miRNA expression in circulation related to
endocrine tumors are waiting to be further explored.
The origin of circulating miRNAs is still not clearly defined [40]. The high-abundance cell-free
circulating miRNAs derive primarily from blood and endothelial cells, and tumor-derived miRNAs
are possibly among the moderate or low abundance range which highlights the importance of the
accurate detection of moderate-low abundance miRNAs [17,24,40]. The overexpressed miRNAs can
originate directly from tumor tissues [17]. By cross-referencing these with the tissue miRNA expression
we identified 3 miRNAs commonly dysregulated in both tissue and circulation. MiR-203a-3p was
overexpressed both in pNET tissue and serum. Similarly, to our findings, in breast cancer, the same
miR-203a-3p was overexpressed both on a tissue level and in exosomes secreted by tumor cells [41,42].
Functionally, it exhibits oncogenic effects in colon and breast cancer, and through MYC and it influences
taxane sensitivity [41,43,44]. These data raise the possibility that miR-203a-3p may potentially be
originated from tumor cells and can be considered as an oncomiR. However, its low abundance in the
sera of patients with NET limits its wide clinical applicability as a tumor marker. Among downregulated
miRNAs, miR-16-5p and miR-451a were both downregulated in PPGL tissues and sera indicating their
roles as potential tumor suppressors that are well-established in other cancers [45,46].
Based on the expression pattern of 33 miRNAs we were able to separate pNET/PPGL patients from
normal controls even on PPI treatment. Based on serum miRNA expression we could not distinguish
samples of pNET from those of PPGL patients. This may reflect the common enterochromaffin cell
type origin of these tumors [47].
Based on NGS data, several miRNAs showed (mostly inverse) correlation with serum CgA
level. However, after validation on an extended sample set, this correlation remained significant
only in healthy individuals but not in pNET or PGGL patients (except for miR-486-5p in PPGL
patients). This may be due to the loss of the great majority of miRNAs showing correlation with CgA
during tumorigenesis (as the global expression of miRNAs decreased in patients compared to healthy
individuals) or due to technical issues. NGS allows us to detect any miRNA with low or very low
copies but RT-qPCR has a detection limit, in our experimental settings miRNAs with reads <50 UMI
could not be validated with RT-qPCR.
Increased CgA level upon PPI treatment decreases the clinical utility of CgA in neuroendocrine
tumors. Performing ROC analysis, we found that in pNET samples CgA alone was less effective in
discrimination of pNET sera from healthy controls. The addition of miRNAs to CgA increased the
diagnostic value of CgA. Importantly, in patients with pNET with normal CgA level where CgA alone
was not informative, the combination of CgA with a miRNA panel could reach high diagnostic value
(AUC: 0.904).
In pNET patients, the grade, determined by the Ki-67 proliferation index, has an important
impact on prognosis [48]. Although the low sample number represents a limitation of our study,
the expression of miR-451a, let-7i-5p, and miR-30d-5p showed a tendency of an inverse correlation with
a grade in pNET patients. Circulating miR-451a was reported underexpressed in several tumor types
and it was described as an immune-regulatory miRNA [45,49–51] that may explain its dysregulation
according to tumor grade in pNET. Let-7i-5p is a well-known tumor suppressor miRNA which
expression is negatively correlated with prognosis [52]. In several studies, it was underexpressed in
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sera of cancer patients vs. healthy controls [52] but the explanation behind its decreasing expression
and its role in pNET patients with higher-grade remains to be clarified. MiR-30d-5p was also
reported downregulated in tumor (hepatocellular carcinoma) cells and secreted exosomes and its high
expression in hepatocellular carcinoma exhibited improved overall survival [53]. These data suggest
that miR-30d-5p, measured both in tissue and in liquid biopsy samples, may indeed have a role in
relation to tumor grade, progression, and survival.
Previously, in pNET, only one study investigated circulating miRNA levels compared to healthy
controls [30]. The authors found a very similar miRNA expression profile compared to healthy
volunteers [30]. Only miR-193b was described to be more abundant in the serum of patients and
it was also more abundant in pNET tissue compared to islet cells. However, by analyzing both
tissue and serum samples of 6 patients, there was a much lower correlation between expression
levels in serum and tissue compared to the mean correlation coefficient within the same tissue [30].
In another study, 5 miRNAs were identified differentially expressed in the sera of pancreatic ductal
adenocarcinoma patients compared to pNET but no comparison between pNET and healthy controls
was performed [54]. None of these 5 miRNAs showed overlap with our results comparing pNET
vs. controls. In a very recent publication, 6 upregulated and 11 downregulated miRNAs were
identified in plasma exosome fraction of pNET patients (no functionality reported) compared to
chronic pancreatitis [55]. Again, none of the identified miRNAs was identical to those in our study
although they had different starting material, different measurement methods, and most importantly,
they compared their data to chronic pancreatitis.
The decrease of miR-486-5p and miR-30d-5p was detected in patients with genetically determined
PGGLs (mutation in either SDHB, RET, VHL, or NF1 genes) compared to sporadic cases. Let-7b-5p,
let-7i-5p, miR-30d-5p, and miR-486-5p were downregulated in SDHB mutant cases compared to
SDHB wild type cases indicating that the etiology of PPGL may influence the circulating miRNA pool.
This observation needs further studies because no data about serum and tissue miRNA differences
between sporadic and genetic PPGL cases were found. Four studies investigated circulating miRNAs in
PPGLs [27,36,56,57]. No significant difference was demonstrated between benign and malignant cases
but elevated levels of miR-96-5p; miR-182-5p and miR-21-3p in PPGL patients compared to healthy
controls were reported [27,36,56]. We could not confirm these results probably due to differences in
experimental design (mirVana™ PARIS™ Kit vs. miRNeasy Serum Kit for isolation; TaqMan assays vs.
QIAseq™ miRNA Library Kit and droplet digital PCR vs. next-generation sequencing).
As a summary, we assessed for the first time the diagnostic accuracy of circulating miRNAs
in relation to CgA in patients with pNET. Using the miRNA profile, we were able to discriminate
pNET/PPGL samples from healthy controls, and a global downregulation of circulating miRNA pool
was observed in patients with neuroendocrine tumors compared to healthy individuals. Similarly,
to CgA, miRNA signature alone was not applicable as a biomarker for PPGL/pNET if PPI treatment
is administered. However, the combination of a set of miRNAs together with CgA, even in the
most challenging group (pNET patients with low CgA level or receiving PPI treatment) represents a
promising diagnostic tool.
4. Materials and Methods
4.1. Patients and Controls
Altogether, 74 consecutive serum samples sent for CgA measurement to the Department of
Laboratory Medicine, Semmelweis University were collected (Table 5) between 1 November 2017 and
24 July 2019. Samples were obtained from patients with pancreas nonfunctioning neuroendocrine
tumor (pNET, n = 25), with pheochromocytoma-paraganglioma (PPGL, n = 20) and from healthy
individuals (n = 29 samples from 24 unrelated cases). PPGL and healthy individuals treated with PPI
were included as controls because in clinical practice elevated CgA levels most often can be found in
these cases.
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Table 5. Patient characteristics. The following paired samples are from the same healthy control with and without PPI treatment: 45 + 46; 47 + 48; 67 + 68; 33 + 49;
69 + 70.
Sample ID. Sex Age at Sampling Group CgA (ng/mL;Ref: 19.4–98.1)
PPGL: Benign/Malignant;
pNET: Grade G1-G2-G3 Experiment
51 F 12 PPGL (PCC) 548.6 benign (pr) NGS & qPCR
52 M 41 PPGL (PCC) 10870 benign (pr) NGS & qPCR
53 M 51 PPGL (SDHB mutation associated. PCC; no other malignant tumor yet) 863.4 benign (pr) NGS & qPCR
18 F 47 PPGL (MEN2 assoc. PCC) 402.9 malignant (rec & met) qPCR
19 F 45 PPGL (PCC) 128.1 malignant (rec) qPCR
23 F 67 PPGL (PCC) 749.6 benign (pr) qPCR
20 M 56 PPGL (PGL) 8166 malignant (rec & met) qPCR
56 M 40 PPGL (SDHB mutation associated PGL) 2265 malignant (rec & met) NGS & qPCR
57 F 69 PPGL (PCC) 1375 malignant (rec & met) NGS & qPCR
21 F 44 PPGL (PGL) 273 malignant (rec & met) qPCR
62 F 48 PPGL (PCC) 2409 benign (pr) NGS & qPCR
28 M 20 PPGL (PCC) 809.5 NA qPCR
22 F 35 PPGL (NF1 mutation associated PCC; no other malignant manifestation) 1602 malignant (rec & met) qPCR
64 F 35 PPGL (PCC) 487.9 benign (pr) NGS & qPCR
26 M 24 PPGL (VHL mutation associated PCC; no other malignant tumor) 63.2 malignant (bilateral) qPCR
24 F 69 PPGL (PCC) 2295 malignant (rec & met) qPCR
29 M 21 PPGL (PCC) 104.1 benign (pr) qPCR
27 F 62 PPGL (PCC) 115 benign (pr) qPCR
66 F 15 PPGL (SDHB mutation associated PCC) 470.8 malignant (rec & met) NGS & qPCR
25 M 36 PPGL (PCC) 1037.4 malignant (rec & met) qPCR
1 M 75 pNET 34.2 G1 qPCR
54 F 58 pNET 191.5 NA NGS & qPCR
55 M 67 pNET 176.6 G3 NGS & qPCR
2 M 57 pNET 35.2 G2 qPCR
3 F 62 pNET 62.2 G2 qPCR
4 M 77 pNET 67.9 G2 qPCR
58 F 66 pNET 162.7 NA NGS & qPCR
59 M 52 pNET 448.5 G2 NGS & qPCR
5 F 62 pNET 44.2 G2 qPCR
60 M 72 pNET 1679 G2 NGS & qPCR
61 F 61 pNET 543.6 G2 NGS & qPCR
6 M 39 pNET 327.4 G3 qPCR
63 F 47 pNET 1009 G2 NGS & qPCR
7 M 68 pNET 219.2 G2 qPCR
65 M 74 pNET 104.5 G1 NGS & qPCR
8 M 42 pNET 190.1 G3 qPCR
9 F 48 pNET 115.4 NA qPCR
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Table 5. Cont.
Sample ID. Sex Age at Sampling Group CgA (ng/mL;Ref: 19.4–98.1)
PPGL: Benign/Malignant;
pNET: Grade G1-G2-G3 Experiment
10 F 82 pNET 79.1 G1 qPCR
11 F 76 pNET 132 G2 qPCR
12 F 58 pNET 51.5 G1 qPCR
13 M 75 pNET 2490.8 NA qPCR
14 F 64 pNET 4163 G2 qPCR
15 F 59 pNET 275.7 NA qPCR
16 M 72 pNET 49.8 G2 qPCR
17 M 73 pNET 34.4 NA qPCR
74 M 77 healthy control 38.5 na qPCR
38 M 71 healthy control 53.7 na qPCR
40 F 49 healthy control 12.7 na qPCR
31 M 49 healthy control 41.5 na qPCR
76 M 44 healthy control 39.8 na NGS & qPCR
36 F 68 healthy control 100.4 na qPCR
30 F 13 healthy control 18 na qPCR
34 M 40 healthy control 40.2 na qPCR
35 F 69 healthy control 48.7 na qPCR
41 F 47 healthy control 93 na qPCR
39 F 63 healthy control 55 na qPCR
75 M 65 healthy control 39 na qPCR
37 M 55 healthy control 57.2 na qPCR
73 M 47 healthy control 34 na NGS & qPCR
43 F 16 healthy control 52.6 na qPCR
42 F 33 healthy control 68.4 na qPCR
72 F 46 healthy control 42.8 na NGS & qPCR
32 F 58 healthy control 80.2 na qPCR
71 M 37 healthy control 27.7 na NGS & qPCR
45 F 72 healthy control without PPI 494 na qPCR
46 F 72 healthy control on PPI 5775 na qPCR
47 F 62 healthy control without PPI 198.9 na qPCR
48 F 62 healthy control on PPI 516 na qPCR
67 F 39 healthy control without PPI 42.3 na NGS & qPCR
68 F 39 healthy control on PPI 197.8 na NGS & qPCR
33 M 64 healthy control without PPI 186.7 na qPCR
49 M 64 healthy control on PPI 595.4 na qPCR
69 F 46 healthy control without PPI 45.6 na NGS & qPCR
70 F 46 healthy control on PPI 278 na NGS & qPCR
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All patients with pNET (12 females, 13 males; avg age: 63.4 years) had metastatic disease.
Low-CgA (<100 ng/mL) pNET group consisted of 9, high-CgA (>100 ng/mL) pNET group consisted
of 16 patients. Grade of pNET was determined according to WHO 2017 classification of tumors of
endocrine organs based on the Ki-67 index (Table 5) [58].
PPGL group consisted of 12 females and 8 males with an average age of 41.8 years. Of them,
8 were benign, 11 were malignant (1 bilateral, 1 locally receive, and 9 metastatic) and there was no
information available in one case. 14 of the 20 PPGL cases were sporadic, while 6 cases were associated
with germline gene mutations in one of the PPGL susceptibility genes (Table 5). All PPGL patients had
elevated CgA levels (avg. CgA: 1751 ng/mL).
Altogether 24 healthy controls were included in the study. Among 29 control samples, 10 sera from
5 healthy volunteers were collected with and without proton pump inhibitor (PPI) treatment. Samples
from these individuals were included if high-dose PPI at least for 2 weeks were administered [11].
In our discovery analysis, we used 8 control samples from 6 healthy individuals, 2 samples were taken
from two cases after PPI treatment. None of the controls had the endocrine disease, tumor, or renal
insufficiency. Eight samples obtained from patients with pNET and 8 samples obtained from PPGL
patients were evaluated. In our validation set, we used all samples used in the discovery analysis
along with 17 additional samples obtained from pNET, 12 samples obtained from PPGL patients,
and 21 samples obtained from healthy controls (Table 5). Clinical information was retrieved from
the Semmelweis University medical information system. The study was approved by the Hungarian
National Public Health Center (NPHC: 41189-7/2018/EÜIG, 13 December 2018) and the Scientific and
Research Committee of the Medical Research Council of Ministry of Health, Hungary (ETT-TUKEB
4457/2012/EKU, 2 February 2012).
4.2. Sample Handling and RNA Extraction
Upon arriving samples were immediately processed for sera separation by centrifugation with
3000× g for 10 min at 4 ◦C. Then, samples were aliquoted and refrigerated at −20 ◦C until further
processing. Samples for RNA isolation were further processed by centrifugation with 16,000× g for
15 min at 4 ◦C to deplete platelets.
CgA measurements were done as part of the routine diagnostics using an IVD qualified competitive
radioimmunassay method (Chromogranin A kit; REF: CGA-RIACT; Cisbio Bioassays, Codolet, France)
following the manufacturer instructions on RIA-mat-280 gamma counter (Byk-Sangtec Diagnostica,
Dietzenbach, Germany).
For total RNA extraction containing small RNA fraction miRNeasy Serum/Plasma Kit (Qiagen,
Cat #217184, Hilden, Germany) was applied. Custom cel-miR-39 spike-in control was added to samples
during RNA extraction following the manufacturer’s instruction (Qiagen, Cat # 219610) [26]. Cellular
contamination of serum samples was studied by evaluation of expression of miRNAs related to red
blood cells and platelets.
4.3. miRNA Expression Profiling by Next-Generation Sequencing
MiRNA expression profiling and NGS data analysis were done as we earlier reported [26,59].
For miRNA sequencing, libraries were prepared using 5 ul RNA and the QIAseq™ miRNA Library
Kit (Qiagen, Cat #331505) following the manufacturer’s instructions. Next-generation sequencing
was run on Illumina MiSeq instrument using MiSeq Reagent Kit v3 150-cycle (MS-102-3001, Illumina,
San Diego, CA, USA. For count normalization TMM was applied as it is one of the best performing
algorithm for comprehensive miRNA profiling studies [60].
4.4. RT-qPCR Validation of NGS Results
For validation TaqMan Advanced miRNA cDNA Synthesis Kit (Cat#: A28007, Thermo Fisher
Scientific, Waltham, MA, USA) was applied. The expression of miRNAs was determined using
individual Advanced TaqMan MicroRNA Assays (Assay IDs: cel-miR-39-3p: 478293_mir, hsa-let-7b-5p:
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478575_mir; hsa-let-7i-5p: 478375_mir; hsa-miR-143-3p: 477912_mir; hsa-miR-203a-3p: 478316_mir;
hsa-miR-30d-5p: 478606_mir; hsa-miR-451a: 478107_mir; hsa-miR-486-5p: 478128_mir). Expression
levels were calculated by the ddCt method, and fold changes were obtained using the formula 2-ddCt.
All measurements were done in triplicates.
4.5. Literature Mining for Tissue-Serum miRNA Expression Cross-Referencing
To investigate the potential origin of serum miRNAs and to compare serum and tissue miRNA
expression profiles, we collected data of miRNA expression profiling studies performed on pNET
(7 studies) [29–35] and PPGL (5 studies) [27,28,36–38] by PubMed search. We cross-referenced our
findings with data retrieved from these studies.
4.6. Statistical Analysis
Shapiro-Wilks test was applied to reveal data distribution. A comparison of differential expression
was done by unpaired T-test or Mann–Whitney U test and one-way ANOVA followed by Tukey
post-hoc test depending on data distribution and grouping. P-value adjustments were applied by
Benjamini–Hochberg. For hierarchical cluster analysis, complete linkage clustering with Kendall’s Tau
distance measuring method was used. The receiver–operator characteristic (ROC) analysis of CgA and
miRNAs’ were used for their discriminatory role between different groups. Binary logistic regression
analyses were applied to evaluate the relationships between miRNAs and the incidence of PPGL/pNET
and to find the best logistic model. Diagnostic accuracy was calculated as: Accuracy = (TN + TP)/
(TN + TP + FN + FP) = (Number of correct assessments)/(Number of all assessments). (TN: true
negative; TP: true positive; FN: false negative; FP: false positive).
p-Value < 0.05 was considered significant. Statistical analyses were done using the R statistical
programming language.
5. Conclusions
As a summary, we assessed for the first time the diagnostic accuracy of circulating miRNAs
in relation to CgA in patients with pNET. Using the miRNA profile, we were able to discriminate
pNET/PPGL samples from healthy controls, and a global downregulation of circulating miRNA pool
was observed in patients with neuroendocrine tumors compared to healthy individuals.
In a comparison of pNET or PPGL groups with controls, levels of CgA, and miRNAs showed
significant differences. If samples from controls treated with PPI were included either CgA or miRNA
signature alone was not applicable as biomarker for PPGL/pNET. In addition, neither CgA nor any
miRNA alone was able to discriminate low CgA pNET patients from controls treated with PPI. However,
the combination of CgA concentration and expression level of miRNAs in a regression model yielded
higher AUC compared to those obtained using individual markers, demonstrating that our model
was effective in distinguishing different groups in every comparison. Our results are in line with
previous findings showing that in other cancer types, independently of individually being significantly
different or not, combining more factors in a regression model increases the discriminatory value of
biomarkers [61,62]. Therefore, the combination of a set of miRNAs together with CgA, even in the
most challenging group (pNET patients with low CgA level or receiving PPI treatment) represents a
promising diagnostic tool.
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AUC area under curve
CgA chromogranin A
miRNA micro-RNA
MYC MYC proto-oncogene, bHLH transcription factor
NET Neuroendocrine tumors
NF1 neurofibromin 1
NF-NET nonfunctioning neuroendocrine tumor
NGS next-generation sequencing
PCC pheochromocytoma
PGL paragangliomas
pNET pancreatic neuroendocrine tumor
PPGL pheochromocytoma-paraganglioma
PPI proton-pump inhibitor
RET ret proto-oncogene
RIA radioimmunoassay
ROC receiver-operating characteristic
SDHB succinate dehydrogenase complex iron-sulfur subunit B
UMI unique molecular index
VHL von Hippel–Lindau tumor suppressor
VIPoma vasoactive intestinal peptide producing neuroendocrine tumor
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